A selection of major announcements
1. China Evergrande plans to sell the Shanghai North Bund project for 663 million yuan
$EVERGRANDE (03333.HK)$It was announced that on December 14, 2023, Evergrande Real Estate Group, a subsidiary of the company, signed an agreement with Everbright Xinglong Trust. The subsidiary transferred its interest in the project company to the transferee at a total cost of RMB 663 million. The project company is an enterprise engaged in real estate development and is responsible for the development of the North Bund project in Shanghai.
2. China Eastern Airlines Co., Ltd. plans to increase the capital of Sichuan Airlines Co., Ltd. by 1.2 billion yuan
$CHINA EAST AIR (00670.HK)$An announcement was issued, and the company's board of directors deliberated and passed the “Proposal on the Company's Capital Increase in Sichuan Airlines Co., Ltd.” It was agreed that the company would participate in the Sichuan Airlines Co., Ltd. capital increase project in the same proportion and increase the capital of Sichuan Airlines Co., Ltd. by 1.2 billion yuan in the form of “currency+non-monetary assets”.
3. Hanson Pharmaceuticals: Three innovative drugs included in the new national health insurance catalogue
$HANSOH PHARMA (03692.HK)$According to the announcement, the following three innovative drugs of the Group have been included in the new “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023)” (“National Health Insurance Catalogue”) issued by the National Medical Security Administration of China: the self-developed class 1 innovative drug Saint Laurel® for the treatment of anemia caused by chronic kidney disease (CKD); imitinofovir tablets and morpholinidazole sodium chloride injections.
4. Minimally invasive medicine: Heart Vein Medical Technology plans to allocate a total of 107.481 million new A-shares, with a net raise of about 1,809 million yuan
$MICROPORT (00853.HK)$According to the announcement, Heart Vein Medical Technology has signed subscription agreements with 17 subscribers. They are securities investment fund management companies, securities companies, securities company asset management plans, qualified overseas institutional investors, private equity funds, insurance company asset management products, and other qualified investors that meet the requirements of the China Securities Regulatory Commission. According to the subscription agreement, Heart Vein Medical Technology has agreed to distribute and distribute, and the subscribers have agreed to subscribe for a total of 107.481 million new A-shares. After the subscription is completed, the issued share capital of Heart Vein Medical Technology owned by the Group will be diluted from about 46.34% to about 40.32%. The total proceeds from the subscription will be approximately RMB 1,809 million.
5. China Antibody plans to issue 56.834,700 shares at a discount of about 18.35%, with a net raise of HK$73.182 million
$SINOMAB BIO-B (03681.HK)$It was announced that a total of 56.834,700 new shares were issued to 15 independent third parties, equivalent to 5.21% of the expanded share capital; each share was 1.29 yuan, a discount of 18.35% from the closing price on the previous trading day (14th). The net proceeds of $73.18 million are intended for marketing and commercialization of sucilizumab, commercial production and post-marketing production site transfer, marketing application and extension research work; clinical trials of shucilizumab for the treatment of mild cognitive impairment; and clinical research on M17 for the treatment of atopic dermatitis.
Important matters
$EVERGRANDE (03333.HK)$Plans to sell the Shanghai North Bund project for 663 million yuan
$CHINA EAST AIR (00670.HK)$: It is planned to increase the capital of Sichuan Airlines Co., Ltd. by 1.2 billion yuan
$SHANGHAI PECHEM (00338.HK)$: It is proposed to sign a new framework agreement with Baishawan Branch and Sinopec Reserve
$MICROPORT (00853.HK)$: Heart Vein Medical Technology plans to allocate a total of 107.481 million new A-shares with a net raise of approximately $1,809 million
$SINOMAB BIO-B (03681.HK)$It is proposed to discount approximately 18.35% and issue 56.834,700 shares for a net raise of HK$73.182 million
Pharmaceutical Innovation
$LEPU BIO-B (02157.HK)$: MRG004A for the treatment of pancreatic cancer was granted orphan drug qualification by the FDA
$HANSOH PHARMA (03692.HK)$: Three innovative drugs have been included in the new national health insurance catalogue
$CIRC (01763.HK)$: Sodium iodide capsules for atomic high technology treatment successfully entered the latest national medical insurance drug catalogue
$HBM HOLDINGS-B (02142.HK)$Signed a license agreement with Seagen Inc. for HBM9033
Repurchase cancellation
$TENCENT (00700.HK)$On December 14, 1.31 million shares were repurchased at a cost of HK$403 million
$AIA (01299.HK)$On December 14, 2,067,600 shares were repurchased at a cost of HK$135 million
$HSBC HOLDINGS (00005.HK)$Repurchase of 199.16 million shares at a cost of HK$121 million on December 13
$LI NING (02331.HK)$Repurchase of 6.241,000 shares at a cost of HK$118 million on December 14
$SUNSHINE PAPER (02002.HK)$Repurchase of 11.5 million shares at a cost of HK$35.424,600 on December 14
$ESR (01821.HK)$Repurchase of 3 million shares at a cost of HK$29.85 million on December 14
$SINOPEC CORP (00386.HK)$Repurchase of 10.382 million shares at a cost of HK$39.9987 million on December 14
$YUM CHINA (09987.HK)$On December 13, 76,300 shares were repurchased at a cost of 3 million US dollars
$COSCO SHIP HOLD (01919.HK)$On December 14, 2,513 million shares were repurchased at a cost of HK$17.648 million
$SWIRE PACIFIC A (00019.HK)$On December 14, 253,000 shares were repurchased at a cost of HK$15.152 million
$ZHONGYU ENERGY (03633.HK)$Repurchase of 2.5 million shares at a cost of HK$14.23 million on December 14
$CONCH CEMENT (00914.HK)$On December 14, it spent 9.964 million yuan to buy back 460,000 A-shares
$HAIER SMARTHOME (06690.HK)$On December 14, it spent 9.111,400 yuan to repurchase 450,000 A-shares
edit/new
